Volunteers at a Newcastle based cancer charity have been left stunned after yobs targeted its base two nights in a row
OVERLAND PARK, Kan., Aug. 29, 2014 /PRNewswire-iReach/ — The 6th Annual Optimist International's Kansas District Annual Childhood Cancer Benefit Golf Tournament, held on August 8 at the Falcon Ridge Golf Course in Lenexa, raised $11,000 in proceeds
( European Society of Cardiology ) New ESC registries are being launched on cardiac oncology and acute coronary syndromes (ACS).
The Mesothelioma Applied Research Foundation invites its supporters, donors, and community at large to join the crowd at the Today show, on September 26, to raise awareness of mesothelioma, an aggressive and vicious cancer. (PRWeb August 29, 2014) Read the full story at http://www.prweb.com/releases/2014/08/prweb12130579.htm
European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to …
New research suggests that how quickly mesothelioma progresses after treatment may predict the likelihood of survival better than treatment response. (PRWeb August 29, 2014) Read the full story at http://www.prweb.com/releases/2014/08/prweb12128203.htm
Wake Forest Baptist Medical Center has received an $18 million, five-year grant from the National Cancer Institute's Community Oncology Research Program to design and conduct community-based, multi-center screening, prevention and control cancer clinical trials.
* Phase II study to assess MEDI-4736 in colorectal cancer * Move (NasdaqGS: MOVE – news) may open large new market for experimental drug * AstraZeneca (NYSE: AZN – news) shares up 2 percent (Adds sales forecasts, detail on competitors, latest shares) LONDON, Aug 29 (Reuters) – Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno …
FOUR men from York are setting of on a 750 cycling challenge across Vietnam to raise money for a cancer charity, and are staging a special event to help raise cash this weekend.
Hopes for AstraZeneca's promising cancer drug pipeline were boosted on Friday by news the company had moved its immuno-oncology medicine MEDI-4736 into a mid-stage study in colorectal cancer.